Ifosfamide, carboplatin and etoposide combined with 41.8°C whole body hyperthermia for malignant pleural mesothelioma

A. Bakhshandeh; I. Bruns; A. Traynor; H. I. Robins; K. Eberhardt; A. Demedts; E. Kaukel; G. Koschel; U. Gatzemeier; Th Kohlmann; K. Dalhoff; E. M. Ehlers; Y. Gruber; R. Zumschlinge; S. Hegewisch-Becker; S. O. Peters; G. J. Wiedemann

doi:10.1016/S0169-5002(02)00536-6

Ifosfamide, carboplatin and etoposide combined with 41.8°C whole body hyperthermia for malignant pleural mesothelioma

A. Bakhshandeh^*, I. Bruns, A. Traynor, H. I. Robins, K. Eberhardt, A. Demedts, E. Kaukel, G. Koschel, U. Gatzemeier, Th Kohlmann, K. Dalhoff, E. M. Ehlers, Y. Gruber, R. Zumschlinge, S. Hegewisch-Becker, S. O. Peters, G. J. Wiedemann

^*Corresponding author for this work

24 Citations (Scopus)

Abstract

We performed a phase II study combining 41.8°C whole body hyperthermia with ICE chemotherapy, i.e. ifosfamide (5 g/m²), carboplatin (300 mg/m²) and etoposide (150 mg/m² on days 2 and 3), administered every 4 weeks, for patients with malignant pleural mesothelioma. Of 27 chemonäive, non-metastatic patients enrolled, 25 patients were evaluable for response. Overall response rate was 20% (five partial remissions; 95% CI 8.9-39.1%). Median survival time from the start of treatment for all patients was 76.6 weeks (95% CI 65.4-87.8 weeks). Progression free survival for all patients measured 29.6 weeks (95% CI 24.4-34.7 weeks). One year overall survival was 68% and 2 year overall survival was 20%. Major treatment toxicities included grade 3/4 neutropenia and thrombocytopenia in 74 and 33% of treatment cycles, respectively. One patient died due to sepsis. These promising results are consistent with continued clinical investigation; a phase III clinical trial with whole body hyperthermia as the independent variable has been initiated.

Original language	English
Journal	Lung Cancer
Volume	39
Issue number	3
Pages (from-to)	339-345
Number of pages	7
ISSN	0169-5002
DOIs	https://doi.org/10.1016/S0169-5002(02)00536-6
Publication status	Published - 01.03.2003

Research Areas and Centers

Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0169-5002(02)00536-6

Cite this

Bakhshandeh, A., Bruns, I., Traynor, A., Robins, H. I., Eberhardt, K., Demedts, A., Kaukel, E., Koschel, G., Gatzemeier, U., Kohlmann, T., Dalhoff, K., Ehlers, E. M., Gruber, Y., Zumschlinge, R., Hegewisch-Becker, S., Peters, S. O., & Wiedemann, G. J. (2003). Ifosfamide, carboplatin and etoposide combined with 41.8°C whole body hyperthermia for malignant pleural mesothelioma. Lung Cancer, 39(3), 339-345. https://doi.org/10.1016/S0169-5002(02)00536-6

@article{4b55dbfc86c14cc1ae8819a7f366c93e,

title = "Ifosfamide, carboplatin and etoposide combined with 41.8°C whole body hyperthermia for malignant pleural mesothelioma",

abstract = "We performed a phase II study combining 41.8°C whole body hyperthermia with ICE chemotherapy, i.e. ifosfamide (5 g/m2), carboplatin (300 mg/m2) and etoposide (150 mg/m2 on days 2 and 3), administered every 4 weeks, for patients with malignant pleural mesothelioma. Of 27 chemon{\"a}ive, non-metastatic patients enrolled, 25 patients were evaluable for response. Overall response rate was 20% (five partial remissions; 95% CI 8.9-39.1%). Median survival time from the start of treatment for all patients was 76.6 weeks (95% CI 65.4-87.8 weeks). Progression free survival for all patients measured 29.6 weeks (95% CI 24.4-34.7 weeks). One year overall survival was 68% and 2 year overall survival was 20%. Major treatment toxicities included grade 3/4 neutropenia and thrombocytopenia in 74 and 33% of treatment cycles, respectively. One patient died due to sepsis. These promising results are consistent with continued clinical investigation; a phase III clinical trial with whole body hyperthermia as the independent variable has been initiated.",

author = "A. Bakhshandeh and I. Bruns and A. Traynor and Robins, {H. I.} and K. Eberhardt and A. Demedts and E. Kaukel and G. Koschel and U. Gatzemeier and Th Kohlmann and K. Dalhoff and Ehlers, {E. M.} and Y. Gruber and R. Zumschlinge and S. Hegewisch-Becker and Peters, {S. O.} and Wiedemann, {G. J.}",

year = "2003",

month = mar,

day = "1",

doi = "10.1016/S0169-5002(02)00536-6",

language = "English",

volume = "39",

pages = "339--345",

journal = "Lung Cancer",

issn = "0169-5002",

number = "3",

}

Bakhshandeh, A, Bruns, I, Traynor, A, Robins, HI, Eberhardt, K, Demedts, A, Kaukel, E, Koschel, G, Gatzemeier, U, Kohlmann, T, Dalhoff, K, Ehlers, EM, Gruber, Y, Zumschlinge, R, Hegewisch-Becker, S, Peters, SO & Wiedemann, GJ 2003, 'Ifosfamide, carboplatin and etoposide combined with 41.8°C whole body hyperthermia for malignant pleural mesothelioma', Lung Cancer, vol. 39, no. 3, pp. 339-345. https://doi.org/10.1016/S0169-5002(02)00536-6

TY - JOUR

T1 - Ifosfamide, carboplatin and etoposide combined with 41.8°C whole body hyperthermia for malignant pleural mesothelioma

AU - Bakhshandeh, A.

AU - Bruns, I.

AU - Traynor, A.

AU - Robins, H. I.

AU - Eberhardt, K.

AU - Demedts, A.

AU - Kaukel, E.

AU - Koschel, G.

AU - Gatzemeier, U.

AU - Kohlmann, Th

AU - Dalhoff, K.

AU - Ehlers, E. M.

AU - Gruber, Y.

AU - Zumschlinge, R.

AU - Hegewisch-Becker, S.

AU - Peters, S. O.

AU - Wiedemann, G. J.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - We performed a phase II study combining 41.8°C whole body hyperthermia with ICE chemotherapy, i.e. ifosfamide (5 g/m2), carboplatin (300 mg/m2) and etoposide (150 mg/m2 on days 2 and 3), administered every 4 weeks, for patients with malignant pleural mesothelioma. Of 27 chemonäive, non-metastatic patients enrolled, 25 patients were evaluable for response. Overall response rate was 20% (five partial remissions; 95% CI 8.9-39.1%). Median survival time from the start of treatment for all patients was 76.6 weeks (95% CI 65.4-87.8 weeks). Progression free survival for all patients measured 29.6 weeks (95% CI 24.4-34.7 weeks). One year overall survival was 68% and 2 year overall survival was 20%. Major treatment toxicities included grade 3/4 neutropenia and thrombocytopenia in 74 and 33% of treatment cycles, respectively. One patient died due to sepsis. These promising results are consistent with continued clinical investigation; a phase III clinical trial with whole body hyperthermia as the independent variable has been initiated.

AB - We performed a phase II study combining 41.8°C whole body hyperthermia with ICE chemotherapy, i.e. ifosfamide (5 g/m2), carboplatin (300 mg/m2) and etoposide (150 mg/m2 on days 2 and 3), administered every 4 weeks, for patients with malignant pleural mesothelioma. Of 27 chemonäive, non-metastatic patients enrolled, 25 patients were evaluable for response. Overall response rate was 20% (five partial remissions; 95% CI 8.9-39.1%). Median survival time from the start of treatment for all patients was 76.6 weeks (95% CI 65.4-87.8 weeks). Progression free survival for all patients measured 29.6 weeks (95% CI 24.4-34.7 weeks). One year overall survival was 68% and 2 year overall survival was 20%. Major treatment toxicities included grade 3/4 neutropenia and thrombocytopenia in 74 and 33% of treatment cycles, respectively. One patient died due to sepsis. These promising results are consistent with continued clinical investigation; a phase III clinical trial with whole body hyperthermia as the independent variable has been initiated.

UR - http://www.scopus.com/inward/record.url?scp=0037374232&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(02)00536-6

DO - 10.1016/S0169-5002(02)00536-6

M3 - Journal articles

C2 - 12609573

AN - SCOPUS:0037374232

SN - 0169-5002

VL - 39

SP - 339

EP - 345

JO - Lung Cancer

JF - Lung Cancer

IS - 3

ER -

Ifosfamide, carboplatin and etoposide combined with 41.8°C whole body hyperthermia for malignant pleural mesothelioma

Abstract

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this